{"transactions":[{"id":698600,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":27114,"kind":"person","name":"Kaul Inderjit","position":1,"cik":"0002095703","reported_name":"Kaul Inderjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-03T22:05:15.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":12147,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shall vest on November 14, 2026; an additional 45% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the Consultant Option shall vest on the tenth day following the date of the Company's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date."}],"balance_after":12147,"derivative":{"exercise_price":3.97,"expiration_date":"2036-08-02","underlying":"Common Stock","underlying_shares":12147},"source":{"system":"sec-edgar","filing":"0002095703-26-000006","document":"form4-08032026_100811.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000209570326000006/form4-08032026_100811.xml","form_type":"4"}},{"id":747479,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":27114,"kind":"person","name":"Kaul Inderjit","position":1,"cik":"0002095703","reported_name":"Kaul Inderjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-05T22:00:09.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in four equal quarterly installments at a rate of 1/4 of the total number of shares every three months, with the first 1/4 vesting on the date that is three months following June 3, 2026 and an additional 1/4 vesting every three months thereafter, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":4.68,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0002095703-26-000004","document":"form4-06052026_060605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000209570326000004/form4-06052026_060605.xml","form_type":"4"}},{"id":822529,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":27114,"kind":"person","name":"Kaul Inderjit","position":1,"cik":"0002095703","reported_name":"Kaul Inderjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-01T20:15:08.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":12169,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date."}],"balance_after":12169,"derivative":{"exercise_price":6.03,"expiration_date":"2036-03-30","underlying":"Common Stock","underlying_shares":12169},"source":{"system":"sec-edgar","filing":"0002095703-26-000002","document":"form4-04012026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000209570326000002/form4-04012026_040401.xml","form_type":"4"}},{"id":959356,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":27114,"kind":"person","name":"Kaul Inderjit","position":1,"cik":"0002095703","reported_name":"Kaul Inderjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-12-23T21:15:21.000Z","date":"2025-12-22","kind":"grant","planned":false,"acquired":true,"shares":364504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the option shall vest on November 14, 2026; an additional 45% of the option shall vest on the tenth day following the date of the Issuer's public announcement that it has achieved, on a statistically significant basis, the primary endpoint of its Phase 3 confirmatory trial of roluperidone in schizophrenia at the 12-week timepoint; and the remaining 30% of the option shall vest on the tenth day following the date of the Issuer's public announcement of safety data from the 40-week relapse assessment phase; provided, however, in each case, that the Reporting Person is providing services pursuant to that certain consulting agreement dated November 14, 2025 on each such vesting date."}],"balance_after":364504,"derivative":{"exercise_price":3.98,"expiration_date":"2035-12-21","underlying":"Common Stock","underlying_shares":364504},"source":{"system":"sec-edgar","filing":"0002095703-25-000007","document":"form4-12232025_041215.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000209570325000007/form4-12232025_041215.xml","form_type":"4"}},{"id":995183,"issuer":{"id":6245,"kind":"organization","name":"Minerva Neurosciences, Inc."},"owners":[{"id":27114,"kind":"person","name":"Kaul Inderjit","position":1,"cik":"0002095703","reported_name":"Kaul Inderjit","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-11-18T21:49:27.000Z","date":"2025-11-14","kind":"grant","planned":false,"acquired":true,"shares":9500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option vest in equal quarterly installments over three years with the first installment vesting on February 14, 2026, subject in each case to the continued service of the Reporting Person as a non-employee director as of such vesting date."}],"balance_after":9500,"derivative":{"exercise_price":4.11,"expiration_date":"2035-11-13","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0002095703-25-000005","document":"form4-11182025_091123.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1598646/000209570325000005/form4-11182025_091123.xml","form_type":"4"}}]}